• Priyanka Samal, Vinay Goyal, Mamta B Singh, and M V Padma Srivastava.
• Department of Neurology, All India Institute of Medical Sciences, New Delhi, India.
• Ann Indian Acad Neur. 2020 Jan 1; 23 (1): 32-37.

ObjectivesPatients with muscle-specific kinase (MuSK)-positive myasthenia are generally considered to have a grave prognosis. We present our experience of patients with myasthenia with different antibody status. This is followed by a short discourse on previous studies and the current view on MuSK-positive myasthenia, focusing on the associated prejudice.Materials And MethodsThis study compares 23 patients with MuSK-positive myasthenia with 55 patients with acetylcholine receptor-positive myasthenia and 9 patients with double-seronegative myasthenia at a tertiary level center.ResultsWe did not find any significant difference in terms of clinical characteristics, treatment response to immunosuppressants, long-term prognosis, and quality of life.ConclusionSeropositivity for antibodies should not be used in isolation to guide the management or predict the prognosis. Undue negative prognostication may affect the morale of patient. Clinical features and response to therapy in addition to antibody status must be considered before planning therapy.Copyright: © 2006-2019 Annals of Indian Academy of Neurology.

5 keywords...

hide…